The European Commission (EC) has granted full Marketing Authorization to luspatercept for the treatment of anemia in adult patients with nontransfusion-dependent beta thalassemia. The centralized Marketing Authorization approves use of luspatercept in all European Union (EU) member states, as well as Norway, Iceland, and Liechtenstein. ...
Advertisement
Advertisement
The approval of the treatment provides patients with an alternative to a product that has historically been in shortage.
Drs. Kambhampati and Thiruvengadam discuss their study investigating the cost effectiveness of pola-R-CHP in DLBCL.
The 60-day mortality rate was around twice as high in patients with KMT2A rearrangement.
While NPM1 mutations impacted CR rates, they had “no impact” on RFS and OS after each line of salvage therapy.
Axicabtagene ciloleucel showed a significant improvement in OS over standard of care in relapsed or refractory LBCL.
Novel therapies and “game-changing drugs” have made a major impact on the treatment of myeloma, Dr. Wong said.
Patients with clinical progression had a significantly shorter median OS from their first relapse.
Revumenib is a potent, selective oral inhibitor of interaction between menin and KMT2A.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Trending on MashupMD
American Society of Hematology
Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study
Raul Cordoba, MD, PhD
Raul Cordoba, MD, PhDKey Points. Fully automated classification of mature
flowcytometry
hematology
lymsm
Frontiers
Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia
Benlazar S M A
Benlazar S M AAllogeneic stem cell transplantation still represent
aml
leusm
finance.yahoo.com
FDA Puts Clinical Hold On Gilead’s Magrolimab/Azacitidine Combo Trials In Blood Cancer Settings
Mikkael A. Sekeres, MD, MS
Mikkael A. Sekeres, MD, MSThe FDA has placed a partial clinical hold on Gilead
leusm
mdssm
medRxiv
Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional
Michael Hallek
Michael HallekBackground Long COVID is a post-severe acute respira
longcovid
ACUTE MYELOID LEUKEMIA
AGGRESSIVE B-CELL LYMPHOMA
CHRONIC LYMPHOCYTIC LEUKEMIA
MYELOMA
ACUTE MYELOID LEUKEMIA
